Skip to main content

Table 4 Excess Economic Burden Estimates of Antimicrobial Resistance

From: Estimating the burden of antimicrobial resistance: a systematic literature review

Study Exposure Group Control Group Country Method Excess Cost Estimate (2013 USD)
Cost per case
[135] MDR TB Susceptible TB Germany Stepwise Calculation 110,063
[135] XDR TB Susceptible TB Germany Stepwise Calculation 145,679
[143] MDR TB Susceptible TB Europe Stepwise Calculation 62,931
[143]) XDR TB Susceptible TB Europe Stepwise Calculation 215,038
[56] MRSA BSI Non-nosocomial-infected patients South Korea Matching 21,832
Annual cost per stated country or stated region
[141] Resistant Streptococcus pneumonia Susceptible Streptococcus pneumonia USA Multistate model 236,495,000
[57] MRSA No MRSA USA Multistate model 7,848,223,600
[142] Artemisinin resistant malaria No resistance High endemicity regions Decision Tree 385,000,000
Global economic cost
[15] Resistance globally (doubling of current infection rates and 100% resistance) Lower rates of resistance (a 40% resistance increase from current rates) Global Total Factor Productivity model 14,228,000,000 less GDP produced in 2050 compared to 2050 in a scenario with lower resistance
[55] Resistance globally (100% resistance rate) No resistance Global Computable General Equilibrium model 3,158,862,360 less GDP produced in 2050 compared to 2050 with no resistance